These innovative molecules represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose https://haarismcco009560.wssblogs.com/39018510/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide